Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Zillow Group Inc Class A (ZG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Zillow Group Inc Class A — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $287.68 (market cap $39.89B), while Zillow Group Inc Class A trades at $32.19 (market cap $7.36B). The key difference: Alnylam Pharmaceuticals, Inc. is far larger — about 5.4× Zillow Group Inc Class A's market cap. Which is the better fit depends on your goals.
| ALNY | ZG | |
|---|---|---|
Market Cap | $39.89B | $7.36B |
Sector | Health | Media |
52-Week High | $491.22 | $86.76 |
52-Week Low | $278.09 | $29.14 |
Enterprise Value | $38.15B | $7.00B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
Zillow Group (ZG) trades at $32.00, down 3.64% on the day, with a neutral technical signal and mixed earnings history. The company reported a return to profitability in 2025 with net income of $23 million, though valuation ratios like a P/E of 128 remain elevated. Recent news highlights multiple securities class action lawsuits filed against the company, creating investor uncertainty.
The outlook is cautiously optimistic given analyst consensus targets near $57.80, but risks from litigation and competitive pressures in the real estate tech sector warrant attention. Revenue growth and execution on profitability targets are key catalysts for stock performance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Zillow Group Inc Class A
Zillow Group is an Internet-based real estate company that has historically focused on deriving ad revenue from third-party brokers on online marketplaces such as Zillow.com, Trulia, and HotPads. More recently it has shifted its focus to iBuying via the Zillow Offers platform.
Read more on ZG →
